Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | O2 |
| Molecular Weight | 31.9988 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=O
InChI
InChIKey=MYMOFIZGZYHOMD-UHFFFAOYSA-N
InChI=1S/O2/c1-2
| Molecular Formula | O2 |
| Molecular Weight | 31.9988 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Oxygen is a chemical element with atomic number 8. Diatomic oxygen constitutes 20.8% of the Earth's atmosphere. Diatomic oxygen is used by complex life forms such as animals, in cellular respiration. Medical oxygen is widely used in clinical practice to provide a basis for most modern anaesthetic techniques; to restore the tissue oxygen tension towards normal by improving oxygen availability in a wide range of conditions such as shock, severe haemorrhage, coronary occlusion, carbon monoxide poisoning, major trauma; to aid the resuscitation of the critically ill, when the circulation is impaired; to aid in neonatal resuscitation; to treat acute severe headache in adults diagnosed with cluster headache.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0009060 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24206183 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseNormobaric oxygen is widely recommended for patients with acute myocardial infarction. The randomized phase 3 clinical trial, however, did not demonstrate reduction in 1-year all-cause mortality compared to ambient air group. |
|||
| Primary | Unknown Approved UseMedical oxygen is widely used in clinical practice to provide a basis for most modern anesthetic techniques; to restore the tissue oxygen tension towards normal by improving oxygen availability in a wide range of conditions such as shock, severe hemorrhage, coronary occlusion, carbon monoxide poisoning, major trauma. |
|||
| Primary | Unknown Approved UseMedical oxygen is widely used in clinical practice to treat acute severe headache in adults diagnosed with a cluster headache. |
|||
| Primary | Unknown Approved UseMedical oxygen is widely used in clinical practice to restore the tissue oxygen tension towards normal by improving oxygen availability in a wide range of conditions such as shock, severe hemorrhage, coronary occlusion, carbon monoxide poisoning, major trauma. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). | 2003-07 |
|
| Induction of T-type calcium channel gene expression by chronic hypoxia. | 2003-06-20 |
|
| Redox regulation of HIF-1alpha levels and HO-1 expression in renal medullary interstitial cells. | 2003-06 |
|
| Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. | 2003-05-02 |
|
| The cellular oxygen tension regulates expression of the endoplasmic oxidoreductase ERO1-Lalpha. | 2003-05 |
|
| Retinal oxygen: fundamental and clinical aspects. | 2003-04 |
|
| Use of helium-oxygen mixtures in the treatment of acute asthma: a systematic review. | 2003-03 |
|
| Heliox vs air-oxygen mixtures for the treatment of patients with acute asthma: a systematic overview. | 2003-03 |
|
| Hyperbaric oxygen for treating wounds: a systematic review of the literature. | 2003-03 |
|
| Oxygen administration in infants. | 2003-03 |
|
| Vascular endothelial growth factor in the cerebrospinal fluid of infants who died of sudden infant death syndrome: evidence for antecedent hypoxia. | 2003-02 |
|
| Suppression of tumor necrosis factor-alpha by beta2-adrenoceptor activation: role of mitogen-activated protein kinases in renal mesangial cells. | 2003-01 |
|
| Airway chemotransduction: from oxygen sensor to cellular effector. | 2002-12-15 |
|
| Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. | 2002-12-15 |
|
| Hypoxia and beta 2-agonists regulate cell surface expression of the epithelial sodium channel in native alveolar epithelial cells. | 2002-12-06 |
|
| Increased migration of murine keratinocytes under hypoxia is mediated by induction of urokinase plasminogen activator. | 2002-12 |
|
| Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. | 2002-12 |
|
| Adaptive responses to oxidative damage in three mutants of Caenorhabditis elegans (age-1, mev-1 and daf-16) that affect life span. | 2002-11 |
|
| Hyperbaric oxygen for cyclophosphamide-induced cystitis. | 2002-11 |
|
| Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. | 2002-11 |
|
| Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). | 2002-10-25 |
|
| The role of hypoxia-inducible signaling pathway in nickel carcinogenesis. | 2002-10 |
|
| Control of the hypoxic response in Drosophila melanogaster by the basic helix-loop-helix PAS protein similar. | 2002-10 |
|
| Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging. | 2002-08-30 |
|
| NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? | 2002-08 |
|
| Response of VEGF expression to amino acid deprivation and inducers of endoplasmic reticulum stress. | 2002-08 |
|
| Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. | 2002-07-05 |
|
| Oxygen therapy for infants with chronic lung disease. | 2002-07 |
|
| Inhibitors of mitochondrial complex I attenuate the accumulation of hypoxia-inducible factor-1 during hypoxia in Hep3B cells. | 2002-05 |
|
| Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. | 2002-05 |
|
| The dietary flavonoid quercetin modulates HIF-1 alpha activity in endothelial cells. | 2002-04-26 |
|
| Role of mitochondrial oxidant generation in endothelial cell responses to hypoxia. | 2002-04-01 |
|
| Hypoxia increases leptin expression in human PAZ6 adipose cells. | 2002-04 |
|
| Serum SP-D is a marker of lung injury in rats. | 2002-04 |
|
| Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. | 2002-03-01 |
|
| Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. | 2002-02-15 |
|
| Stabilization of hypoxia-inducible factor-1alpha is involved in the hypoxic stimuli-induced expression of vascular endothelial growth factor in osteoblastic cells. | 2002-01-07 |
|
| Basic toxicological approach has been effective in two poisoned patients with amitraz ingestion: case reports. | 2002-01 |
|
| Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. | 2001-12-21 |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001-11-30 |
|
| Differential expression of adrenomedullin and its receptor component, receptor activity modifying protein (RAMP) 2 during hypoxia in cultured human neuroblastoma cells. | 2001-11 |
|
| A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. | 2001-11 |
|
| Hypoxia reduces alveolar epithelial sodium and fluid transport in rats: reversal by beta-adrenergic agonist treatment. | 2001-11 |
|
| Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. | 2001-09 |
|
| Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. | 2001-09 |
|
| Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs. | 2001-09 |
|
| Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. | 2001-08-28 |
|
| Dependence of excitotoxic neurodegeneration on mitochondrial aconitase inactivation. | 2001-08 |
|
| Recovery from oxidant-mediated lung injury: response of metallothionein, MIP-2, and MCP-1 to nitrogen dioxide, oxygen, and ozone exposures. | 2001-08 |
|
| Sensory nerves promote ozone-induced lung inflammation in mice. | 2001-07-15 |
Patents
Sample Use Guides
Medical oxygen is administered by inhalation through the lungs. The major exception is when a metered supply is fed into the oxygenator of an extracorporeal circulation of a cardiopulmonary by-pass system. For a cluster headache, oxygen should be administered as soon as possible after the onset of the attack, via a non-rebreathing facemask at a flow of 6 to 12 l/min for approximately 15 minutes.
Route of Administration:
Respiratory
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:01 GMT 2025
by
admin
on
Mon Mar 31 18:22:01 GMT 2025
|
| Record UNII |
S88TT14065
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
10236-8
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
19211-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10248-3
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
JECFA EVALUATION |
INS-948
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10242-6
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10233-5
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
DSLD |
1363 (Number of products:4)
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10240-0
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2703-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-VATC |
QV03AN01
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10245-9
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-ATC |
V03AN01
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2705-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10239-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10235-0
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10244-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST | 1.1.1 | ||
|
LOINC |
10247-5
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10232-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
3147-6
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
3148-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10241-8
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST | 1.4 | ||
|
LOINC |
10238-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10234-3
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
11556-8
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10243-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2706-0
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10226-9
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10237-6
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
3149-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
14864-3
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
NCI_THESAURUS |
C1940
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
DSLD |
1827 (Number of products:15)
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
28648-4
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
10246-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
2704-5
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
||
|
LOINC |
28649-2
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1234886
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
7782-44-7
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
100000090500
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
DTXSID2037681
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
7806
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
m8333
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
D010100
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
4235
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
OXYGEN
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | Description: A colourless gas; odourless. Solubility: One volume dissolves in about 32 volumes of water and in about 7 volumes of ethanol (~750 g/l) TS, both at apressure of 101.3 kPa and 20?C. Category: Gas for inhalation. Storage: Oxygen should be kept as compressed gas or liquid at cryogenic temperature, in appropriate containers complying withthe safety regulations of the national authority. Valves or taps should not be lubricated with oil or grease. Labelling: An ISO standard1 requires that cylinders containing oxygen intended for medical use should bear the name of thecontents in legible and permanent characters and, preferably, also the molecular formula O2.1 International Standard 32. Gas cylinders for medical use - marking for identification of content. International Organization for Standardization, Switzerland, 1977. Additional information: In the analysis of medicinal gases certain tests are not intended for hospital pharmacists. They are solely applicable by laboratories equipped with the specialized apparatus. Requirements: Oxygen contains not less than 99.5% v/v of O2. | ||
|
S88TT14065
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
S88TT14065
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
231-956-9
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
977
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
15379
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
C722
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
5054
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
25805
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
Triplet oxygen
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
SUB14733MIG
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY | |||
|
DB09140
Created by
admin on Mon Mar 31 18:22:01 GMT 2025 , Edited by admin on Mon Mar 31 18:22:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|